This recent readout follows successful data from another combination including Braftovi in mCRC.

PFE stock decreased 30.0% from a peak of $40.71 on January 23, 2020, to $28.49 on March 23, 2020, compared to a peak-to-trough decline of 33.9% for the S&P 500. PFE stock diminished 57.9% from a peak ...

Pfizer Inc. PFE on Tuesday shared news regarding its BRAFTOVI regimen for treating metastatic colorectal cancer. Pfizer ...

Pfizer (PFE) stock is in focus as colorectal cancer therapy Braftovi as part of a combination regimen succeeds in a late-stage trial. Read more here.

In lieu of a Super Bowl ad this year, Pfizer has unveiled a year-long cancer campaign that aims to encourage screening.

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.

Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, while reaffirming its modest 2026 guidance that rattled investors in December ...

In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a placebo.

Pfizer made one thing clear this week: It's officially back in the obesity race.

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation models.

$2.90 per share would value Pfizer stock at less than 9 times earnings, Pfizer pays a 6.5% dividend yield -- and hasn't cut its dividend even once in the last 15 years. Even single-digit earnings ...